Skip to main content

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis


CSR Summary

Not Available


NCT Number

Not Available


Data Specification

Annotated CRF

Available upon data request approval

Product Info

Generic Name
Infliximab
Product Name
REMICADE®
Therapeutic Area
Muscle, Bone, and Cartilage Diseases
Enrollment
101
% Female
73.4%
% White
96.0%
Product Class
Antirheumatic Agents - Biologic Response Modifiers
Sponsor Protocol Number
C0168T14
Data Partner
Johnson & Johnson
Condition Studied
Arthritis, Rheumatoid
Mean/Median Age (Years)
52.0

Supporting Documentation

Clinical Study Report
Collected Datasets
Data Definition Specification
Annotated Case Report Form
Study Phase 
2

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.